International Journal of Hematology

, Volume 91, Issue 3, pp 446–455

Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan

Authors

    • Division of Oncology and HematologyNational Cancer Center Hospital East
  • Tomohiro Kinoshita
    • Department of Hematology and OncologyNagoya University Graduate School of Medicine
  • Takashi Watanabe
    • Hematology DivisionNational Cancer Center Hospital
  • Kenichi Yoshimura
    • Clinical Trials and Practice Support Division, Center for Cancer Control and Information ServicesNational Cancer Center
  • Rumiko Okamoto
    • Department of ChemotherapyTokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • Takaaki Chou
    • Department of Internal MedicineNiigata Cancer Center Hospital
  • Michinori Ogura
    • Department of Hematology and Cell TherapyAichi Cancer Center
  • Masami Hirano
    • Department of HematologyFujita Health University School of Medicine
  • Hideki Asaoku
    • Clinical LaboratoryHiroshima Red Cross Hospital, Atomic-Bomb Survivors Hospital
  • Mitsutoshi Kurosawa
    • Department of Hematology, National Hospital OrganizationHokkaido Cancer Center
  • Yoshiharu Maeda
    • Department of ChemotherapyTokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • Ken Omachi
    • Department of Hematology and OncologyTokai University School of Medicine
  • Yukiyoshi Moriuchi
    • Department of HematologySasebo Municipal General Hospital
  • Masaharu Kasai
    • Department of HematologySapporo Hokuyu Hospital
  • Kazunori Ohnishi
    • Department of Internal MedicineHamamatsu University School of Medicine
  • Nobuyuki Takayama
    • Second Department of Internal MedicineKyorin University
  • Yasuo Morishima
    • Department of Hematology and Cell TherapyAichi Cancer Center
  • Kensei Tobinai
    • Hematology DivisionNational Cancer Center Hospital
  • Harumi Kaba
    • Clinical Trials and Practice Support Division, Center for Cancer Control and Information ServicesNational Cancer Center
  • Seiichiro Yamamoto
    • Clinical Trials and Practice Support Division, Center for Cancer Control and Information ServicesNational Cancer Center
  • Haruhiko Fukuda
    • Clinical Trials and Practice Support Division, Center for Cancer Control and Information ServicesNational Cancer Center
  • Masahiro Kikuchi
    • Department of Pathology, School of MedicineFukuoka University
  • Tadashi Yoshino
    • Department of PathologyOkayama University, Medical School
  • Yoshihiro Matsuno
    • Department of Surgical PathologyHokkaido University
  • Tomomitsu Hotta
    • National Hospital OrganizationNagoya Medical Center
  • Masanori Shimoyama
    • National Cancer Center Hospital
Original Article

DOI: 10.1007/s12185-010-0533-9

Cite this article as:
Itoh, K., Kinoshita, T., Watanabe, T. et al. Int J Hematol (2010) 91: 446. doi:10.1007/s12185-010-0533-9

Abstract

The Japan Clinical Oncology Group conducted two multicenter phase II trials in 200 patients with advanced Hodgkin lymphoma (HL) in the 1990s. Among 181 patients whose histopathological specimens were available and reviewed by 6 hematopathologists, 167 (92.3%) were diagnosed with HL. Five-year overall survival (OS) among these 167 patients was 88.3%, including 89.2% among nodular sclerosis and 82.2% among mixed cellularity cases. International prognostic score was not closely associated with OS. Seven unfavorable prognostic factors for OS on univariate analysis were male, B symptoms, clinical stage of III or IV, elevated serum LDH, elevated alkaline phosphatase, elevated β2-microglobulin, and pathological subtype (mixed cellularity and lymphocyte depletion). On multivariate analysis, male [HR 3.30 (95% CI 1.15–9.52, p = 0.027)] and elevated serum LDH [HR 2.41 (95% CI 1.07–5.43, p = 0.034)] were independent factors for OS. Based on these prognostic factors, the 5-year OS was 95.7% in the low-risk group (no adverse factor), 87.9% in the intermediate-risk group (1 adverse factor) and 73.3% in the high-risk group (2 adverse factors). This simple prognostic model for HL warrants further validation studies.

Keywords

International prognostic score Multicenter phase II trial Prognostic factor Overall survival Male gender LDH

Copyright information

© The Japanese Society of Hematology 2010